Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant
- Vibrato Medical
MONTIRVINE, Calif.–(BUSINESS WIRE)–Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that it has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA, and has also received a $1.5M National Institutes of Health (NIH) grant. Together, funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of PAD, from the convenience of their home. Read more…
Related Reading
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Orthopedic / Regulatory Affairs
Robert Cohen of Stryker Named Chair of AdvaMed’s Digital Health Tech Division Board of Directors
January 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.
Resource / Business Development
From Category to Capabilities: Rethinking Procurement Through the Business Lens
December 17, 2025
Read how shifting to a capability-driven procurement model enables medtech organizations to better align sourcing decisions with business strategy, and strengthen cross-functional collaboration.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Regulatory Affairs / Small Business
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors
December 11, 2025
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.
News / Health Access / Small Business
Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System
December 8, 2025
NAPLES, Fla., Dec. 4, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that its Catalyst Fracture Shoulder System has received FDA 510(k) clearance for additional indications that now include anatomic (total or hemi) shoulder procedures, giving surgeons flexibility to treat complex proximal humeral fractures (PHFs) with a single, streamlined platform for both anatomic and reverse replacements. In anatomic indications, the Catalyst Fracture System utilizes Catalyst’s ellipsoid head design, shown to better restore natural anatomy compared to traditional spherical head designs on the market today.
Event / Regulatory Affairs
Medical Device Submissions Workshop Series: Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 25, 2026
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Event / Regulatory Affairs
Medical Device Submissions Series: Premarket Approval (PMA) Workshop
8:30 am – 4:30 pm ET
February 26-27, 2026
Learn key PMA Submissions strategies to build a strong submissions, align with FDA expectations, and reduce delays.
Event / Regulatory Affairs
Medical Device Submissions Series: 510(k) & De Novo Workshop
Now available to purchase!
Join industry leaders for the in-depth 510(k) & De Novo Workshop for real-world case studies, submissions tips and best practices.
News / Health Access / Small Business
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
December 2, 2025
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of prostate cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the Vanquish System for prostate tissue ablation. FDA clearance was supported by positive 12-month follow-up data on the first 110 patients enrolled in the company’s ongoing VAPOR 2 clinical study. The clearance marks a critical milestone for the company and enables a commercial launch of the Vanquish System.